Last reviewed 2026-04-22 · How we verify

NexoBrid

NexoBrid is a topical enzymatic debriding agent containing bromelain that selectively removes necrotic tissue from burn wounds.

NexoBrid is a topical enzymatic debriding agent containing bromelain that selectively removes necrotic tissue from burn wounds. Used for Thermal burns requiring eschar removal.

At a glance

Mechanism of action

NexoBrid uses bromelain, a proteolytic enzyme derived from pineapple, to enzymatically digest and separate eschar (dead tissue) from viable tissue in thermal burns. This selective enzymatic debridement allows for faster removal of necrotic material compared to traditional surgical debridement, reducing the need for surgical intervention and promoting faster wound healing.

Approved indications

• Thermal burns requiring eschar removal

Common side effects

• Transient hyperemia (redness)
• Mild bleeding or oozing
• Pain at application site
• Allergic reactions

Key clinical trials

• A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care (PHASE3)
• Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries
• A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NexoBrid CI brief — competitive landscape report
• NexoBrid updates RSS · CI watch RSS
• MediWound Ltd portfolio CI